Laboratorios Farmaceuticos Rovi SA

41L

Company Profile

  • Business description

    Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

  • Contact

    Julian Camarillo, 35
    Madrid28037
    ESP

    T: +34 913756230

    E: [email protected]

    https://www.rovi.es

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    2,188

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,162.6035.500.39%
CAC 408,358.763.33-0.04%
DAX 4025,405.34143.700.57%
Dow JONES (US)49,590.2086.130.17%
FTSE 10010,140.7016.100.16%
HKSE26,608.48376.691.44%
NASDAQ23,733.9062.560.26%
Nikkei 22553,742.931,803.043.47%
NZX 50 Index13,655.0728.22-0.21%
S&P 5006,977.2710.990.16%
S&P/ASX 2008,827.8036.500.42%
SSE Composite Index4,165.2944.861.09%

Market Movers